This Week in the Roadhouse Pharmacy

THE ROADHOUSE PHARMACY: There’s a great deal of interest in the Bio-tech sector at the moment, so we have opened our own Pharmacy to keep our readers up to speed.

Regeneus partners with US specialist manufacturer

Regeneus (ASX: RGS) has partnered with US specialist veterinary vaccine manufacturer, Hennessy Research, for the production of the company’s new autologous canine cancer immunotherapy, Kvax. READ MORE…

New Study shows improved outcomes

AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which measures central aortic blood pressures and arterial stiffness noninvasively, has announced that the results of a clinical study which examined treatment of heart failure patients guided by central blood pressure waveform analysis, as measured by SphygmoCor, has been published in the Journal of the American Heart Association. READ MORE…

ASDM licences synthetic bone substitute with University of Sydney

Orthopaedic devices manufacturer, Advanced Surgical Design and Manufacture Limited (ASDM) (ASX: AMT) has executed a global Licence Agreement with The University of Sydney relating to a composite biocompatible ceramic material known as Sr-HT-Gahnite. READ MORE…

Antisense releases Toxicology Study findings

Antisense Therapeutics (ASX: ANP) released results from a chronic toxicity study in monkeys, which it says indicate ATL1102, an antisense oligonucleotide currently under development for the treatment of multiple sclerosis (MS), was well-tolerated when given subcutaneously for a 6-month dosing period at the 2 dose levels tested (1.5 and 3mg/kg/dose). READ MORE…

Nanosonics signs strategic partnership

Nanosonics Limited (ASX: NAN) has entered into a strategic partnership with Miele Professional for the distribution of trophon®EPR in Germany. READ MORE…